PIK3CA and neoplasm: When the receptor activates the ligand, regulatory and anergic mechanisms are initiated, most importantly resulting in inhibition of normal activation and proliferation of tumour-specific T cells, thereby abrogating the PI3K/AKT/mTOR and Ras pathways and consequently the cell-killing effect of tumour-specific T cells [131,132].